Financials in USD. Standardized financial statements.
A compact view of how NexgenRx Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $17.46M | $16.48M | $13.85M | $12.46M | $11.88M | $10.42M | $9.58M | $6.93M | $5.72M | $5.80M |
| Revenue Growth? | +6.0% | +19.0% | +11.1% | +4.9% | +14.0% | +8.7% | +38.2% | +21.1% | -1.2% | 0.0% |
| Cost of Revenue? | $4.22M | $3.35M | $3.03M | $3.97M | $3.39M | $2.32M | $2.06M | $1.44M | $1.27M | $1.19M |
| Gross Profit? | $13.25M | $13.12M | $10.82M | $8.49M | $8.49M | $8.10M | $7.52M | $5.49M | $4.46M | $4.60M |
| Gross Margin? | +75.9% | +79.6% | +78.1% | +68.2% | +71.5% | +77.7% | +78.5% | +79.2% | +77.9% | +79.4% |
| Operating Expenses? | $11.47M | $11.92M | $10.96M | $8.42M | $6.33M | $6.59M | $7.64M | $6.26M | $5.02M | $4.08M |
| Operating Income? | $1.78M | $1.20M | -$143,876 | $79,414.67 | $2.16M | $1.51M | -$123,651.38 | -$767,968.05 | -$567,395.77 | $520,721.17 |
| EBITDA? | $3.00M | $2.32M | $1.03M | $1.68M | $4.33M | $2.45M | $951,520.45 | -$436,427.91 | -$435,546 | $691,481.34 |
| Income Before Tax | $1.93M | $1.03M | -$305,055 | $133,284 | $2.03M | $1.81M | -$288,543.42 | -$718,675.96 | -$635,057.84 | $415,847.7 |
| Income Tax Expense | $645,314 | $412,150 | $26,915 | $155,487.7 | -$2.02M | -$306,455.03 | -$74,938.94 | -$24,023.17 | $3.81 | -$176,289.56 |
| Net Income? | $1.29M | $614,569 | -$331,970 | -$22,203.7 | $4.05M | $2.12M | -$213,603.15 | -$694,652.8 | -$635,057.84 | $592,138.62 |
| EPS? | $0.01 | $0.01 | $-0.00 | $-0.00 | $0.06 | $0.03 | $-0.00 | $-0.01 | $-0.01 | $0.01 |
| Diluted EPS? | $0.01 | $0.01 | $-0.00 | $-0.00 | $0.05 | $0.03 | $-0.00 | $-0.01 | $-0.01 | $0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality